Hypertriglyceridemia: Foundations and Clinical Implications

Description

Learner Objectives

Upon completion of this activity, you should be able to:

Identify the causes of hypertriglyceridemia (HTG) and severe hypertriglyceridemia (sHTG) and their relationship with conditions like metabolic syndrome, diabetes, obesity, and genetic factors.
Recognize the risks associated with sHTG, such as pancreatitis and increased cardiovascular disease profile.

Planning Committee

Michael Miller, MD, FACC

University of Pennsylvania

Disclosure

Consulting Fees/Honoraria: Amarin, Ionis Pharmaceuticals, New Amsterdam Pharmaceuticals, & Novo Nordisk Inc.

Chris Owen, MS, APRN, ACNP-BC, RNFA, FACC

American College of Cardiology
Disclosure
Consultant Fees/Honoraria: SilkRoad

Faculty

Monica Aggarwal, MD, FACC

University of Florida

Disclosure

Consulting Fees/Honoraria: Arrowhead Pharmaceuticals, & National Triglyceride Alliance

Speaker’s Bureau: Ionis Pharmaceuticals

Grant Acknowledgement
Educational grant support for this activity provided by Ionis Pharmaceuticals.

Summary

Availability:

On-Demand

Access expires on Mar 31, 2028

Cost:

FREE

Credit Offered:

0.5 CME Credit

0.5 CNE Credit

0.5 AAPA Credit

0.5 ABIM-MOC Point

0.5 IPCE Credit